Cancer Epidemiology最新文献_第2页

Exploring associations between travel burden, clinical features, and outcomes from head and neck cancer in Scotland, UK 探索英国苏格兰头颈癌的旅行负担、临床特征和预后之间的关系

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-02-12 DOI: 10.1016/j.canep.2026.103012

Melanie Turner , Samuel Kent , Sharon Hanley , Peter Murchie

Background

Geographic inequalities in cancer outcomes are reported internationally, but little is known about associations between geography and head and neck cancer (HNC) in Scotland. We explored how travelling times to health services influences clinical characteristics, stage at diagnosis, treatment, and one-year mortality for HNC in Scotland.

Methods

We conducted a national, population-based, retrospective cohort study using linked administrative and clinical data covering all individuals diagnosed with HNC in Scotland between 2014 and 2019. We calculated and categorised their travelling times to key healthcare facilities and explored associations with key outcomes - HPV-status, stage at diagnosis, treatment received, and one-year mortality. Multivariable regression models adjusted for key confounders.

Results

6692 patients were included. Patients with the longest travelling time (≥ 60 min or island) were less likely to present with advanced-stage disease (OR 0.73, 95 % CI: 0.54–0.98) and were significantly less likely to die within one year (HR 0.64, 95 % CI: 0.46–0.88). No difference was observed in proportion of HPV-positive cancers across travel time categories. There were also no significant differences in proportions receiving surgery or treated within 31 days of diagnosis.

Conclusions

The association between geography and HNC in Scotland is complex and differs from previous studies in other cancers. Patients with the longest travel time had lower risk of advanced stage at presentation and reduced one-year mortality with no apparent difference in HPV-prevalence or treatment access. In context these findings suggest that travelling time disadvantage is not uniform across cancer types and highlights the need for cancer site–specific approaches to monitoring and reducing inequalities. This large, population-based analysis provides the most comprehensive assessment of HNC and geography in Scotland to date. Findings challenge assumptions of consistent travel time disadvantage and can inform policy on equitable cancer care delivery in the pre-pandemic era.

国际上有关于癌症结果的地理不平等的报道，但对苏格兰地理与头颈癌（HNC）之间的关系知之甚少。我们探讨了到卫生服务机构的旅行时间如何影响苏格兰HNC的临床特征、诊断阶段、治疗和一年死亡率。方法：我们进行了一项全国性的、基于人群的回顾性队列研究，使用相关的行政和临床数据，涵盖了2014年至2019年苏格兰所有被诊断为HNC的个体。我们计算并分类了他们到主要医疗机构的旅行时间，并探讨了与关键结果（hpv状态、诊断阶段、接受的治疗和一年死亡率）的关系。调整了关键混杂因素的多变量回归模型。结果共纳入6692例患者。旅行时间最长（≥60 min或island）的患者出现晚期疾病的可能性较低（or 0.73, 95 % CI: 0.54-0.98），一年内死亡的可能性较低（HR 0.64, 95 % CI: 0.46-0.88）。在不同的旅行时间类别中，hpv阳性癌症的比例没有差异。在确诊后31天内接受手术或治疗的比例也无显著差异。在苏格兰，地理位置与HNC之间的关系是复杂的，与之前对其他癌症的研究不同。旅行时间最长的患者在发病时的晚期风险较低，一年死亡率降低，hpv患病率或治疗可及性无明显差异。在此背景下，这些发现表明，旅行时间劣势在不同类型的癌症中并不统一，并强调需要针对癌症部位的方法来监测和减少不平等。这项基于人口的大型分析提供了迄今为止苏格兰HNC和地理最全面的评估。研究结果挑战了持续旅行时间劣势的假设，并可为大流行前时代公平提供癌症护理的政策提供信息。

{"title":"Exploring associations between travel burden, clinical features, and outcomes from head and neck cancer in Scotland, UK","authors":"Melanie Turner , Samuel Kent , Sharon Hanley , Peter Murchie","doi":"10.1016/j.canep.2026.103012","DOIUrl":"10.1016/j.canep.2026.103012","url":null,"abstract":"<div><h3>Background</h3><div>Geographic inequalities in cancer outcomes are reported internationally, but little is known about associations between geography and head and neck cancer (HNC) in Scotland. We explored how travelling times to health services influences clinical characteristics, stage at diagnosis, treatment, and one-year mortality for HNC in Scotland.</div></div><div><h3>Methods</h3><div>We conducted a national, population-based, retrospective cohort study using linked administrative and clinical data covering all individuals diagnosed with HNC in Scotland between 2014 and 2019. We calculated and categorised their travelling times to key healthcare facilities and explored associations with key outcomes - HPV-status, stage at diagnosis, treatment received, and one-year mortality. Multivariable regression models adjusted for key confounders.</div></div><div><h3>Results</h3><div>6692 patients were included. Patients with the longest travelling time (≥ 60 min or island) were less likely to present with advanced-stage disease (OR 0.73, 95 % CI: 0.54–0.98) and were significantly less likely to die within one year (HR 0.64, 95 % CI: 0.46–0.88). No difference was observed in proportion of HPV-positive cancers across travel time categories. There were also no significant differences in proportions receiving surgery or treated within 31 days of diagnosis.</div></div><div><h3>Conclusions</h3><div>The association between geography and HNC in Scotland is complex and differs from previous studies in other cancers. Patients with the longest travel time had lower risk of advanced stage at presentation and reduced one-year mortality with no apparent difference in HPV-prevalence or treatment access. In context these findings suggest that travelling time disadvantage is not uniform across cancer types and highlights the need for cancer site–specific approaches to monitoring and reducing inequalities. This large, population-based analysis provides the most comprehensive assessment of HNC and geography in Scotland to date. Findings challenge assumptions of consistent travel time disadvantage and can inform policy on equitable cancer care delivery in the pre-pandemic era.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103012"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of colonoscopy adherence after positive colorectal cancer screening: Insights from individual and municipality-level data in Flanders 结直肠癌筛查阳性后结肠镜检查依从性的决定因素：来自佛兰德斯个人和市政层面数据的见解

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-01-31 DOI: 10.1016/j.canep.2026.103011

Thao Linh Ha , Thuy Ngan Tran , Sarah Hoeck , Guido Van Hal

Background

Timely follow-up colonoscopy after a positive fecal immunochemical test (FIT) is essential for the effectiveness of colorectal cancer (CRC) screening programs (CRC-SP). However, a substantial proportion of individuals fail to complete diagnostic follow-up. This study aimed to identify individual- and municipality-level factors associated with nonadherence to follow-up colonoscopy in the Flemish CRC-SP.

Methods

Individual-level data from the Flemish Centre for Cancer Detection (CCD), including 26,539 individuals with a positive FIT result in 2019, were linked with publicly available municipality-level indicators to assess demographic, socioeconomic, and healthcare-related characteristics. The outcome was nonadherence to follow-up colonoscopy within one year after a positive FIT result. A multivariable logistic regression model was developed using a structured approach: univariable screening (p < 0.15), multicollinearity assessment, and variable selection using least absolute shrinkage and selection operator (LASSO) regression. A random intercept for province was incorporated to account for potential clustering.

Results

A total of 5021 individuals (18.9 %) did not complete a follow-up colonoscopy within one year after a positive FIT result. In the final multivariable model, older age (65–69: OR = 1.12, 95 % CI: 1.03–1.21, p = 0.006; 70–74: OR = 1.29, 95 % CI: 1.20–1.40, p < 0.001), male gender (OR = 1.14, 95 % CI: 1.07–1.22, p < 0.001), and higher proportions of individuals living alone (OR = 1.02, 95 % CI: 1.00–1.03, p = 0.009) was associated with increased odds of nonadherence. In contrast, having a global medical dossier (GMD) were associated with better adherence (OR = 0.97, 95 % CI = 0.96–0.98, p < 0.001). Variance at the provincial level was negligible.

Conclusions

This study provides evidence to support targeted implementation strategies within the Flemish CRC-SP. Strengthening primary care involvement and addressing social determinants of health may improve follow-up colonoscopy rates and enhance the equity and effectiveness of the screening program.

粪便免疫化学试验（FIT）阳性后及时随访结肠镜检查对于结直肠癌（CRC）筛查计划（CRC- sp）的有效性至关重要。然而，相当大比例的个体未能完成诊断随访。本研究旨在确定佛兰德CRC-SP患者随访结肠镜检查依从性不符合的个人和城市因素。方法弗拉芒癌症检测中心（CCD）的个人数据，包括2019年FIT结果呈阳性的26,539人，与公开的市级指标相关联，以评估人口、社会经济和医疗保健相关特征。结果是在FIT阳性结果后一年内不坚持随访结肠镜检查。采用结构化方法建立了多变量逻辑回归模型：单变量筛选（p <； 0.15），多重共线性评估，以及使用最小绝对收缩和选择算子（LASSO）回归的变量选择。一个随机截距的省份被纳入考虑潜在的聚类。结果共有5021例（18.9 %）患者在FIT阳性后一年内未完成结肠镜随访。在最后的多变量模型中,老年人(65 - 69年:= 1.12,95 % CI: 1.03 - -1.21, p = 0.006;70 - 74年:= 1.29,95 % CI: 1.20 - -1.40, p & lt; 0.001),男性性别(或= 1.14,95 % CI: 1.07 - -1.22, p & lt; 0.001),和更高比例的个人独自生活(或= 1.02,95 % CI: 1.00 - -1.03, p = 0.009)与不依从的几率增加。相比之下，拥有全球医疗档案（GMD）与更好的依从性相关（OR = 0.97, 95 % CI = 0.96-0.98, p <； 0.001）。省一级的差异可以忽略不计。结论：本研究为支持佛兰德CRC-SP有针对性的实施策略提供了证据。加强初级保健的参与和解决健康的社会决定因素可以提高结肠镜检查的随访率，提高筛查项目的公平性和有效性。

{"title":"Determinants of colonoscopy adherence after positive colorectal cancer screening: Insights from individual and municipality-level data in Flanders","authors":"Thao Linh Ha , Thuy Ngan Tran , Sarah Hoeck , Guido Van Hal","doi":"10.1016/j.canep.2026.103011","DOIUrl":"10.1016/j.canep.2026.103011","url":null,"abstract":"<div><h3>Background</h3><div>Timely follow-up colonoscopy after a positive fecal immunochemical test (FIT) is essential for the effectiveness of colorectal cancer (CRC) screening programs (CRC-SP). However, a substantial proportion of individuals fail to complete diagnostic follow-up. This study aimed to identify individual- and municipality-level factors associated with nonadherence to follow-up colonoscopy in the Flemish CRC-SP.</div></div><div><h3>Methods</h3><div>Individual-level data from the Flemish Centre for Cancer Detection (CCD), including 26,539 individuals with a positive FIT result in 2019, were linked with publicly available municipality-level indicators to assess demographic, socioeconomic, and healthcare-related characteristics. The outcome was nonadherence to follow-up colonoscopy within one year after a positive FIT result. A multivariable logistic regression model was developed using a structured approach: univariable screening (p < 0.15), multicollinearity assessment, and variable selection using least absolute shrinkage and selection operator (LASSO) regression. A random intercept for province was incorporated to account for potential clustering.</div></div><div><h3>Results</h3><div>A total of 5021 individuals (18.9 %) did not complete a follow-up colonoscopy within one year after a positive FIT result. In the final multivariable model, older age (65–69: OR = 1.12, 95 % CI: 1.03–1.21, p = 0.006; 70–74: OR = 1.29, 95 % CI: 1.20–1.40, p < 0.001), male gender (OR = 1.14, 95 % CI: 1.07–1.22, p < 0.001), and higher proportions of individuals living alone (OR = 1.02, 95 % CI: 1.00–1.03, p = 0.009) was associated with increased odds of nonadherence. In contrast, having a global medical dossier (GMD) were associated with better adherence (OR = 0.97, 95 % CI = 0.96–0.98, p < 0.001). Variance at the provincial level was negligible.</div></div><div><h3>Conclusions</h3><div>This study provides evidence to support targeted implementation strategies within the Flemish CRC-SP. Strengthening primary care involvement and addressing social determinants of health may improve follow-up colonoscopy rates and enhance the equity and effectiveness of the screening program.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103011"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146080033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prostate cancer in Korea: Nationwide trends in prevalence and medication use during 2011–2021 韩国前列腺癌：2011-2021年全国患病率和用药趋势

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-01-16 DOI: 10.1016/j.canep.2026.102987

Jaehee Jung , Hyunha Kang , Eunjung Choo , Hye-Young Kang , Chang Wook Jeong , Ha-Lim Jeon , Hankil Lee

Introduction

The incidence of prostate cancer (PC) is rapidly increasing with population aging. With the emergence of new androgen receptor-targeting agents beyond androgen deprivation therapy, the treatment paradigm for PC is expected to shift. This study aimed to analyze the epidemiological characteristics and treatment patterns of patients with PC in Korea over the past decade, with a particular focus on drug utilization.

Materials and methods

We conducted a prevalence-based cross-sectional study on all Korean patients who received medical care for PC between 2011 and 2021. Patient characteristics, including age, comorbidities, metastatic status, drug classes, and treatment patterns, were analyzed.

Results

In 2021, the prevalence of PC was 532 per 100,000 adult men, an increase of 170.45 %, from 220 per 100,000 adult men in 2011. The mean age of patients with PC in 2021 was 73.07 years, with more than 80 % aged 65 years or older. Comorbidities, such as diabetes, pulmonary diseases, and mild liver disease, were common. Androgen deprivation therapy remained the most common pharmacological treatment; however, the proportion of its use gradually decreased over time, and the introduction of androgen receptor-targeting agents led to a steady increase in their use.

Conclusions

This study provides real-world evidence of the epidemiology and therapeutic patterns of PC, thereby enhancing the understanding of the current clinical landscape in Korea.

随着人口老龄化，前列腺癌（PC）的发病率正在迅速上升。随着雄激素剥夺疗法之外新的雄激素受体靶向药物的出现，前列腺癌的治疗模式有望发生转变。本研究旨在分析韩国近十年来PC患者的流行病学特征和治疗模式，并特别关注药物使用情况。材料和方法我们对2011年至2021年期间接受PC治疗的所有韩国患者进行了基于患病率的横断面研究。分析患者特征，包括年龄、合并症、转移状态、药物类别和治疗模式。结果2021年，成年男性PC患病率为532 / 10万，比2011年的220 / 10万增加170.45 %。2021年PC患者的平均年龄为73.07岁，超过80% 年龄在65岁及以上。合并症，如糖尿病、肺病和轻度肝病，是常见的。雄激素剥夺疗法仍然是最常见的药物治疗；然而，随着时间的推移，其使用比例逐渐下降，雄激素受体靶向药物的引入导致其使用稳步增加。结论：本研究为PC的流行病学和治疗模式提供了真实的证据，从而增强了对韩国当前临床状况的理解。

{"title":"Prostate cancer in Korea: Nationwide trends in prevalence and medication use during 2011–2021","authors":"Jaehee Jung , Hyunha Kang , Eunjung Choo , Hye-Young Kang , Chang Wook Jeong , Ha-Lim Jeon , Hankil Lee","doi":"10.1016/j.canep.2026.102987","DOIUrl":"10.1016/j.canep.2026.102987","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of prostate cancer (PC) is rapidly increasing with population aging. With the emergence of new androgen receptor-targeting agents beyond androgen deprivation therapy, the treatment paradigm for PC is expected to shift. This study aimed to analyze the epidemiological characteristics and treatment patterns of patients with PC in Korea over the past decade, with a particular focus on drug utilization.</div></div><div><h3>Materials and methods</h3><div>We conducted a prevalence-based cross-sectional study on all Korean patients who received medical care for PC between 2011 and 2021. Patient characteristics, including age, comorbidities, metastatic status, drug classes, and treatment patterns, were analyzed.</div></div><div><h3>Results</h3><div>In 2021, the prevalence of PC was 532 per 100,000 adult men, an increase of 170.45 %, from 220 per 100,000 adult men in 2011. The mean age of patients with PC in 2021 was 73.07 years, with more than 80 % aged 65 years or older. Comorbidities, such as diabetes, pulmonary diseases, and mild liver disease, were common. Androgen deprivation therapy remained the most common pharmacological treatment; however, the proportion of its use gradually decreased over time, and the introduction of androgen receptor-targeting agents led to a steady increase in their use.</div></div><div><h3>Conclusions</h3><div>This study provides real-world evidence of the epidemiology and therapeutic patterns of PC, thereby enhancing the understanding of the current clinical landscape in Korea.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102987"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer 聚（adp -核糖）聚合酶抑制剂（PARPi）在卵巢癌中的应用趋势

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-01-22 DOI: 10.1016/j.canep.2026.102996

Joseph A. Dottino , Katherine E. Baumann , Katharine M. Esselen , Rebecca Costa , Stephanie Argetsinger , Dennis Ross-Degnan , Anita K. Wagner

Background

To assess population-level trends in use of poly (ADP-ribose) polymerase inhibitors (PARPis) among ovarian cancer patients in the years following initial FDA approvals.

Methods

A national, commercial and Medicare Advantage insurance claims database was used to identify patients with ovarian cancer from 2015 to 2021. Year of ovarian cancer diagnosis was categorized by initial period of PARPi approval for treatment indication (2015–2016) and expanded period of PARPi approval for treatment and maintenance indications (2017–2021). Clinical and demographic characteristics were assessed. The primary outcome was proportion of patients with PARPi dispensings. Time from first observed ovarian cancer diagnosis to first observed PARPi dispensing was calculated.

Results

Of 23,165 patients with ovarian cancer, most were 65 years or older (62.8 %) and had Medicare Advantage insurance (66.2 %). More patients diagnosed in the expanded compared to the initial approval period received PARPi (9.8 % vs. 6.6 %, p < 0.0001) and within less time from diagnosis to PARPi initiation (HR: 2.31, 95 % CI 2.06, 2.59). Age over 65 was associated with lower likelihood of PARPi receipt (OR: 0.85, 95 % CI 0.74, 0.98). In the initial approval period, patients residing in non-white zip codes were more likely to receive a PARPi (OR: 1.61, 95 % CI 1.19, 2.18) and frail patients were less likely to receive a PARPi (OR: 0.41, 95 % CI 0.22, 0.78).

Conclusion

Since 2015, PARPi use increased among ovarian cancer patients, and time from diagnosis to PARPi receipt decreased, reflecting expanded PARPi indications over time. Monitoring demographic and clinical characteristics of PARPi recipients may help assess population-level use of novel therapeutics.

本研究旨在评估FDA批准卵巢癌患者使用聚（adp -核糖）聚合酶抑制剂（PARPis）后的人群水平趋势。方法使用国家、商业和联邦医疗保险优势保险索赔数据库识别2015年至2021年的卵巢癌患者。卵巢癌诊断年份按PARPi治疗适应症批准初始期（2015-2016年）和PARPi治疗和维持适应症批准延长期（2017-2021年）进行分类。评估临床和人口学特征。主要终点是使用PARPi配药的患者比例。计算首次观察到卵巢癌诊断至首次观察到PARPi配药的时间。结果在23,165例卵巢癌患者中，大多数年龄在65岁及以上（62.8 %），并有医疗保险优势（66.2% %）。与最初的批准期相比，更多的患者在扩大的批准期接受了PARPi(9.8 % vs. 6.6 %,p <； 0.0001)，并且从诊断到PARPi启动的时间更短（HR: 2.31, 95 % CI 2.06, 2.59）。65岁以上的患者接受PARPi的可能性较低（OR: 0.85, 95 % CI 0.74, 0.98）。在最初的批准期内，居住在非白人邮政编码地区的患者更有可能接受PARPi (OR: 1.61, 95 % CI 1.19, 2.18)，体弱患者更不可能接受PARPi （OR: 0.41, 95 % CI 0.22, 0.78）。结论自2015年以来，卵巢癌患者使用PARPi的人数增加，从诊断到接受PARPi的时间缩短，反映PARPi适应证随着时间的推移而扩大。监测PARPi接受者的人口学和临床特征可能有助于评估新疗法在人群水平上的使用情况。

{"title":"Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer","authors":"Joseph A. Dottino , Katherine E. Baumann , Katharine M. Esselen , Rebecca Costa , Stephanie Argetsinger , Dennis Ross-Degnan , Anita K. Wagner","doi":"10.1016/j.canep.2026.102996","DOIUrl":"10.1016/j.canep.2026.102996","url":null,"abstract":"<div><h3>Background</h3><div>To assess population-level trends in use of poly (ADP-ribose) polymerase inhibitors (PARPis) among ovarian cancer patients in the years following initial FDA approvals.</div></div><div><h3>Methods</h3><div>A national, commercial and Medicare Advantage insurance claims database was used to identify patients with ovarian cancer from 2015 to 2021. Year of ovarian cancer diagnosis was categorized by initial period of PARPi approval for treatment indication (2015–2016) and expanded period of PARPi approval for treatment and maintenance indications (2017–2021). Clinical and demographic characteristics were assessed. The primary outcome was proportion of patients with PARPi dispensings. Time from first observed ovarian cancer diagnosis to first observed PARPi dispensing was calculated.</div></div><div><h3>Results</h3><div>Of 23,165 patients with ovarian cancer, most were 65 years or older (62.8 %) and had Medicare Advantage insurance (66.2 %). More patients diagnosed in the expanded compared to the initial approval period received PARPi (9.8 % vs. 6.6 %, p < 0.0001) and within less time from diagnosis to PARPi initiation (HR: 2.31, 95 % CI 2.06, 2.59). Age over 65 was associated with lower likelihood of PARPi receipt (OR: 0.85, 95 % CI 0.74, 0.98). In the initial approval period, patients residing in non-white zip codes were more likely to receive a PARPi (OR: 1.61, 95 % CI 1.19, 2.18) and frail patients were less likely to receive a PARPi (OR: 0.41, 95 % CI 0.22, 0.78).</div></div><div><h3>Conclusion</h3><div>Since 2015, PARPi use increased among ovarian cancer patients, and time from diagnosis to PARPi receipt decreased, reflecting expanded PARPi indications over time. Monitoring demographic and clinical characteristics of PARPi recipients may help assess population-level use of novel therapeutics.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102996"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146025000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unicentric retrospective study of gastroenteropancreatic neuroendocrine tumors: Updated epidemiological insights 胃肠胰神经内分泌肿瘤的单中心回顾性研究：最新的流行病学见解

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-01-16 DOI: 10.1016/j.canep.2026.102988

Christèle Asmar , Raphaël Asmar , Maria Al Rachid , Carole Kesrouani , Viviane Trak-Smayra , Hampig Raphaël Kourié , Joseph Gharios

Background

Neuroendocrine neoplasms (NENs) are rare tumors, making up 0.5 % of all cancers, with around 65 % found in the gastroenteropancreatic (GEP) system, with increasing occurrence globally in recent years. The World Health Organization (WHO) classifies GEP-NENs into two main groups: neuroendocrine tumors and neuroendocrine carcinomas according to the new 2022 classification.

Aim

To provide updated epidemiological data on GEP-NENs diagnosed at a tertiary referral center in Beirut, Lebanon, using the WHO 2022 classification, and to describe changes in incidence, demographics, and tumor characteristics compared with previously reported data.

Methods

This retrospective study included patients treated at Hotel Dieu de France, from January 2013 to June 2024, with histologically confirmed GEP-NENs and complete medical records available. GEP-NENs were categorized based on their primary site and pathology reports reanalyzed according to the WHO 2022 classification. Data were then collected on patient demographics, primary tumor site, tumor grade and presence of metastasis at diagnosis.

Results

Among 194 NENs diagnosed during the study period, 74 were GEP-NENs (25.2 %). The mean age at diagnosis was 59.8 years, with a male-to-female ratio of 1.61. Of patients with available grading data, 39.0 % were classified as NET G1, 34.4 % as NET G2, and 26.6 % as high-grade disease (NET G3 and NEC combined). Compared with data from the previous decade, a lower proportion of G1 tumors and higher proportions of G2 and G3 tumors were observed, along with higher frequencies of pancreatic and hepatic primaries and lower rates of colonic and duodenal primaries. NET G3 and NECs were most frequently located in the liver, ampulla of Vater, and colon. All colorectal GEP-NENs identified were metastatic at diagnosis.

Conclusion

GEP-NENs in this cohort were more frequently diagnosed with higher histological grades and metastatic disease compared to the previous decade, a pattern observed during a period marked by major socioeconomic disruption and the COVID-19 pandemic.

神经内分泌肿瘤（NENs）是一种罕见的肿瘤，占所有癌症的0.5% %，其中约65 %发现于胃肠胰（GEP）系统，近年来全球发病率不断增加。世界卫生组织（WHO）根据新的2022年分类将GEP-NENs分为两大类：神经内分泌肿瘤和神经内分泌癌。目的利用世卫组织2022分类，提供黎巴嫩贝鲁特一家三级转诊中心诊断的GEP-NENs的最新流行病学数据，并描述与以前报告的数据相比在发病率、人口统计学和肿瘤特征方面的变化。方法回顾性研究纳入2013年1月至2024年6月在法国上帝酒店（Hotel Dieu de France）就诊的患者，患者均有组织学证实的GEP-NENs和完整的医疗记录。根据其原发部位对GEP-NENs进行分类，并根据WHO 2022分类重新分析病理报告。然后收集患者人口统计学、原发肿瘤部位、肿瘤分级和诊断时是否存在转移的数据。结果研究期间诊断的194例NENs中，74例为GEP-NENs（25.2% %）。平均诊断年龄为59.8岁，男女比为1.61。在可获得分级数据的患者中，39.0% %被分类为NET G1, 34.4% %被分类为NET G2, 26.6% %被分类为高级别疾病（NET G3和NEC合并）。与前十年的数据相比，G1肿瘤比例降低，G2和G3肿瘤比例升高，胰腺和肝脏原发频率升高，结肠和十二指肠原发率降低。NET G3和nec最常见于肝脏、壶腹和结肠。所有结直肠GEP-NENs在诊断时均为转移性。与前十年相比，该队列中的gep - nens更频繁地被诊断为更高的组织学分级和转移性疾病，这是在主要社会经济中断和COVID-19大流行期间观察到的一种模式。

{"title":"Unicentric retrospective study of gastroenteropancreatic neuroendocrine tumors: Updated epidemiological insights","authors":"Christèle Asmar , Raphaël Asmar , Maria Al Rachid , Carole Kesrouani , Viviane Trak-Smayra , Hampig Raphaël Kourié , Joseph Gharios","doi":"10.1016/j.canep.2026.102988","DOIUrl":"10.1016/j.canep.2026.102988","url":null,"abstract":"<div><h3>Background</h3><div>Neuroendocrine neoplasms (NENs) are rare tumors, making up 0.5 % of all cancers, with around 65 % found in the gastroenteropancreatic (GEP) system, with increasing occurrence globally in recent years. The World Health Organization (WHO) classifies GEP-NENs into two main groups: neuroendocrine tumors and neuroendocrine carcinomas according to the new 2022 classification.</div></div><div><h3>Aim</h3><div>To provide updated epidemiological data on GEP-NENs diagnosed at a tertiary referral center in Beirut, Lebanon, using the WHO 2022 classification, and to describe changes in incidence, demographics, and tumor characteristics compared with previously reported data.</div></div><div><h3>Methods</h3><div>This retrospective study included patients treated at Hotel Dieu de France, from January 2013 to June 2024, with histologically confirmed GEP-NENs and complete medical records available. GEP-NENs were categorized based on their primary site and pathology reports reanalyzed according to the WHO 2022 classification. Data were then collected on patient demographics, primary tumor site, tumor grade and presence of metastasis at diagnosis.</div></div><div><h3>Results</h3><div>Among 194 NENs diagnosed during the study period, 74 were GEP-NENs (25.2 %). The mean age at diagnosis was 59.8 years, with a male-to-female ratio of 1.61. Of patients with available grading data, 39.0 % were classified as NET G1, 34.4 % as NET G2, and 26.6 % as high-grade disease (NET G3 and NEC combined). Compared with data from the previous decade, a lower proportion of G1 tumors and higher proportions of G2 and G3 tumors were observed, along with higher frequencies of pancreatic and hepatic primaries and lower rates of colonic and duodenal primaries. NET G3 and NECs were most frequently located in the liver, ampulla of Vater, and colon. All colorectal GEP-NENs identified were metastatic at diagnosis.</div></div><div><h3>Conclusion</h3><div>GEP-NENs in this cohort were more frequently diagnosed with higher histological grades and metastatic disease compared to the previous decade, a pattern observed during a period marked by major socioeconomic disruption and the COVID-19 pandemic.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102988"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and survival of head and neck cancers in the United Kingdom 2000–2021 2000-2021年英国头颈癌的发病率和生存率

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-02-11 DOI: 10.1016/j.canep.2026.103018

Andrea Miquel-Dominguez , Eng Hooi Tan , Edward Burn , Antonella Delmestri , Talita Duarte-Salles , Asieh Golozar , Wai Yi Man , Daniel Prieto-Alhambra , Francesc Xavier Avilés-Jurado , Danielle Newby

Background

Understanding the changing burden of head and neck cancers (HNC) is essential to guide public health interventions and inform cancer care strategies.

Methods

We conducted a cohort study using routinely collected primary care data Clinical Practice Research Datalink (CPRD) GOLD from the United Kingdom. Adults aged ≥ 18 years with ≥ 1 year of prior history were included. We estimated crude and age-standardised incidence rates (IRs) and one-, five-, and ten-year survival from 2000 to 2021, stratified by age and calendar year. Findings from CPRD GOLD were compared with primary care data from CPRD Aurum (England only).

Results

There were 12,455 patients with a diagnosis of HNC from CPRD GOLD (69.2 % male; median age 64 years). Crude incidence in GOLD increased from 9.08 (95 % CI: 7.88–10.42) per 100,000 person-years in 2000–15.59 (14.07–17.23) in 2021, with similar trends observed in CPRD Aurum. Age-standardised incidence trends were attenuated overall but remained elevated for oropharyngeal and tongue cancers. Five-year survival improved modestly, from 53.8 % (95 % CI: 51.4–56.3 %) in 2000–2004–58.7 % (56.5–60.9 %) in 2015–2019.

Conclusions

Incidence increases for HNC were attenuated after age standardisation, suggesting a contribution of demographic ageing, although elevations persisted for specific subsites. Small improvements in long term survival highlights more research is needed to improve earlier diagnosis which will lead to better patient outcomes.

背景了解头颈癌（HNC）负担的变化对指导公共卫生干预和癌症护理策略至关重要。方法：我们使用常规收集的英国临床实践研究数据链（CPRD） GOLD初级保健数据进行了一项队列研究。年龄≥ 18岁，既往病史≥ 1年的成人纳入研究对象。我们估计了2000年至2021年的粗发病率和年龄标准化发病率（IRs）以及1年、5年和10年生存率（按年龄和日历年分层）。CPRD GOLD的研究结果与CPRD Aurum（仅英国）的初级保健数据进行了比较。结果12455例CPRD GOLD诊断为HNC（69.2% ，男性，中位年龄64岁）。GOLD的粗发病率从2000年的9.08(95 % CI: 7.88-10.42) / 10万人年增加到2021年的15.59(14.07-17.23)/ 10万人年，在CPRD Aurum也观察到类似的趋势。年龄标准化的发病率趋势总体上减弱，但口咽癌和舌癌的发病率趋势仍然升高。5年生存率略有提高，从2000 - 2004年的53.8 %（95 % CI: 51.4-56.3 %）到2015-2019年的58.7 %（56.5-60.9 %）。结论：年龄标准化后，HNC发病率的增加有所减弱，这表明人口老龄化的贡献，尽管特定亚位点的升高持续存在。长期生存率的微小改善表明，需要更多的研究来改善早期诊断，这将导致更好的患者预后。

{"title":"Incidence and survival of head and neck cancers in the United Kingdom 2000–2021","authors":"Andrea Miquel-Dominguez , Eng Hooi Tan , Edward Burn , Antonella Delmestri , Talita Duarte-Salles , Asieh Golozar , Wai Yi Man , Daniel Prieto-Alhambra , Francesc Xavier Avilés-Jurado , Danielle Newby","doi":"10.1016/j.canep.2026.103018","DOIUrl":"10.1016/j.canep.2026.103018","url":null,"abstract":"<div><h3>Background</h3><div>Understanding the changing burden of head and neck cancers (HNC) is essential to guide public health interventions and inform cancer care strategies.</div></div><div><h3>Methods</h3><div>We conducted a cohort study using routinely collected primary care data Clinical Practice Research Datalink (CPRD) GOLD from the United Kingdom. Adults aged ≥ 18 years with ≥ 1 year of prior history were included. We estimated crude and age-standardised incidence rates (IRs) and one-, five-, and ten-year survival from 2000 to 2021, stratified by age and calendar year. Findings from CPRD GOLD were compared with primary care data from CPRD Aurum (England only).</div></div><div><h3>Results</h3><div>There were 12,455 patients with a diagnosis of HNC from CPRD GOLD (69.2 % male; median age 64 years). Crude incidence in GOLD increased from 9.08 (95 % CI: 7.88–10.42) per 100,000 person-years in 2000–15.59 (14.07–17.23) in 2021, with similar trends observed in CPRD Aurum. Age-standardised incidence trends were attenuated overall but remained elevated for oropharyngeal and tongue cancers. Five-year survival improved modestly, from 53.8 % (95 % CI: 51.4–56.3 %) in 2000–2004–58.7 % (56.5–60.9 %) in 2015–2019.</div></div><div><h3>Conclusions</h3><div>Incidence increases for HNC were attenuated after age standardisation, suggesting a contribution of demographic ageing, although elevations persisted for specific subsites. Small improvements in long term survival highlights more research is needed to improve earlier diagnosis which will lead to better patient outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103018"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Early-onset cancer incidence in the United States by race/ethnicity between 2011 and 2020” [Cancer Epidemiol. 92 (2024) 102632] “2011年至2020年美国按种族/民族划分的早发性癌症发病率”的勘误表[癌症流行病学，92(2024)102632]。

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-02-04 DOI: 10.1016/j.canep.2026.102998

Anjali Gupta , Tomi Akinyemiju

引用次数: 0

Haematological cancer in pregnancy in New South Wales, Australia: A population-based retrospective cohort study 澳大利亚新南威尔士州妊娠期血液病癌症：一项基于人群的回顾性队列研究

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-02-12 DOI: 10.1016/j.canep.2026.103020

Tanmay Bagade , Nadom Safi , Nada Hamad , Antoinette Anazodo , Marc Remond , Elizabeth Sullivan

Background

Pregnancy-associated haematological cancers (PAHC) are rare but may have profound impacts on maternal and neonatal outcomes. We aimed to describe the incidence, survival rates, and perinatal outcomes associated with PAHC in New South Wales (NSW), Australia.

Methods

Utilising seven datasets, we performed a population-based retrospective cohort study, linking data for all women who gave birth in NSW from 1994 to 2013, and tracked mortality outcomes up to 2018. Women and their babies were stratified into three groups: gestational haematological cancer (HC), postpartum HC group, and pregnant women not diagnosed with cancer. Descriptive statistics, incidence, mortality rate, survival probability, and a composite severe maternal morbidity outcome indicator (MMOI) and composite neonatal adverse outcome indicator (NAOI) were calculated and compared between groups. We also conducted a sub-group analysis of women with lymphoma and leukaemia.

Findings

Of the 1786,302 pregnancies included in the cohort, 224 women were diagnosed with PAHC. The overall incidence of PAHC was 12.5/100,000 women giving birth, which increased by 4 % yearly over the study period. The overall mortality rate was 15.5/1000 and 20/1000 women-years in the gestational HC and postpartum HC groups, respectively. Gestational HCs were associated with higher odds of MMOI (AOR 17.39 (95 % CI: 9.88–30.59) and NAOI (AOR 4.69 (95 % CI: 2.43–9.03) compared to postpartum HC and pregnant women not diagnosed with cancer.

Interpretation

Over the two-decade study period, we observed a significant increase in the incidence of PAHCs, with an associated higher maternal and neonatal mortality and morbidity for women with gestational HCs. Our results emphasise the critical importance of decision-making and clinical practice regarding the continuation of pregnancy and cancer management for women diagnosed with PAHCs.

背景：妊娠相关血液癌（PAHC）是罕见的，但可能对孕产妇和新生儿的预后有深远的影响。我们的目的是描述澳大利亚新南威尔士州（NSW）与PAHC相关的发病率、生存率和围产期结局。方法：利用7个数据集，我们进行了一项基于人群的回顾性队列研究，将1994年至2013年在新南威尔士州分娩的所有妇女的数据联系起来，并追踪到2018年的死亡率结果。妇女和她们的婴儿被分为三组：妊娠血液癌（HC）组，产后HC组和未诊断为癌症的孕妇。计算描述性统计数据、发病率、死亡率、生存率以及综合重度孕产妇发病结局指标（MMOI）和新生儿不良结局指标（NAOI），并对两组进行比较。我们还对患有淋巴瘤和白血病的妇女进行了亚组分析。在1786302名孕妇中，有224名妇女被诊断为PAHC。PAHC的总发病率为12.5/10万名分娩妇女，在研究期间每年增加4 %。妊娠期HC组和产后HC组的总死亡率分别为15.5/1000和20/1000妇女年。与产后HC和未确诊癌症的孕妇相比，妊娠期HC与MMOI (AOR 17.39（95 % CI: 9.88-30.59）和NAOI (AOR 4.69（95 % CI: 2.43-9.03）的发生率相关。在20年的研究期间，我们观察到多环芳烃的发病率显著增加，与之相关的孕产妇和新生儿死亡率以及妊娠期hcc妇女的发病率更高。我们的研究结果强调了决策和临床实践对于诊断为多环芳烃的妇女继续妊娠和癌症管理的关键重要性。

{"title":"Haematological cancer in pregnancy in New South Wales, Australia: A population-based retrospective cohort study","authors":"Tanmay Bagade , Nadom Safi , Nada Hamad , Antoinette Anazodo , Marc Remond , Elizabeth Sullivan","doi":"10.1016/j.canep.2026.103020","DOIUrl":"10.1016/j.canep.2026.103020","url":null,"abstract":"<div><h3>Background</h3><div>Pregnancy-associated haematological cancers (PAHC) are rare but may have profound impacts on maternal and neonatal outcomes. We aimed to describe the incidence, survival rates, and perinatal outcomes associated with PAHC in New South Wales (NSW), Australia.</div></div><div><h3>Methods</h3><div>Utilising seven datasets, we performed a population-based retrospective cohort study, linking data for all women who gave birth in NSW from 1994 to 2013, and tracked mortality outcomes up to 2018. Women and their babies were stratified into three groups: gestational haematological cancer (HC), postpartum HC group, and pregnant women not diagnosed with cancer. Descriptive statistics, incidence, mortality rate, survival probability, and a composite severe maternal morbidity outcome indicator (MMOI) and composite neonatal adverse outcome indicator (NAOI) were calculated and compared between groups. We also conducted a sub-group analysis of women with lymphoma and leukaemia.</div></div><div><h3>Findings</h3><div>Of the 1786,302 pregnancies included in the cohort, 224 women were diagnosed with PAHC. The overall incidence of PAHC was 12.5/100,000 women giving birth, which increased by 4 % yearly over the study period. The overall mortality rate was 15.5/1000 and 20/1000 women-years in the gestational HC and postpartum HC groups, respectively. Gestational HCs were associated with higher odds of MMOI (AOR 17.39 (95 % CI: 9.88–30.59) and NAOI (AOR 4.69 (95 % CI: 2.43–9.03) compared to postpartum HC and pregnant women not diagnosed with cancer.</div></div><div><h3>Interpretation</h3><div>Over the two-decade study period, we observed a significant increase in the incidence of PAHCs, with an associated higher maternal and neonatal mortality and morbidity for women with gestational HCs. Our results emphasise the critical importance of decision-making and clinical practice regarding the continuation of pregnancy and cancer management for women diagnosed with PAHCs.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103020"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146173873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association between body fatness and prevalent MGUS in the U.S. general population 在美国普通人群中，身体肥胖和普遍的MGUS之间的关系。

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-02-16 DOI: 10.1016/j.canep.2026.103021

Mengmeng Ji , John H. Huber , Mei Wang , Tuo Lan , Graham A. Colditz , Shi-Yi Wang , Su-Hsin Chang

Objective

Current evidence regarding the association between obesity and monoclonal gammopathy of undetermined significance (MGUS) remains inconsistent. This study aims to evaluate the relationship between objectively measured obesity markers and prevalent MGUS using nationally representative data from the U.S. population.

Method

Data came from the third National Health and Nutrition Examination Survey III (1988–1994) and continuous NHANES (1999–2004). We estimated multivariable-adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) for the association between MGUS and seven obesity markers (i.e., baseline body mass index (BMI), maximum lifetime BMI, waist circumference (WC), waist-hip ratio (WHR), total body fat, fat-free mass, and body fat percentage) using logistic regression. Body composition was assessed using dual-energy X-ray absorptiometry (DXA) in NHANES 1999–2004 and tetrapolar bioelectrical impedance analysis (BIA) in NHANES III.

Results

The study included 200 participants with MGUS in NHANES III (1988–1994) and 164 with MGUS in NHANES 1999–2004, compared with 12,043 participants without MGUS. In multivariate logistic regression analysis with DXA measurements, each 1 %age point increase in body fat percentage was associated with a 4 % higher odds of MGUS (aOR: 1.04, 95 % CI [1.01, 1.07]) and a 6 % higher odds of non-IgM MGUS (aOR: 1.06, 95 % CI [1.02, 1.10]). No statistically significant associations were found between MGUS and other obesity markers, including baseline BMI, maximum lifetime BMI, WC, WHR, and fat-free mass.

Conclusion

Our findings indicate that obesity is associated with an increased odds of MGUS. However, many obesity markers, including the commonly used BMI, do not adequately capture this association.

目的：目前关于肥胖和未确定意义单克隆γ病（MGUS）之间关系的证据仍然不一致。本研究旨在评估客观测量的肥胖标志物与美国人口中普遍存在的MGUS之间的关系。方法：数据来自第三次全国健康与营养检查调查III（1988-1994）和连续的NHANES（1999-2004）。我们使用logistic回归估计了MGUS与7个肥胖指标（即基线体重指数（BMI）、最大终生体重指数、腰围（WC）、腰臀比（WHR）、总体脂、无脂质量和体脂百分比）之间的关联的多变量校正比值比（aORs）和95% %置信区间（CIs）。采用NHANES 1999-2004中的双能x线吸收仪（DXA）和NHANES III中的四极生物电阻抗分析法（BIA）评估体成分。结果：该研究包括NHANES III（1988-1994）中200名MGUS参与者和NHANES 1999-2004中164名MGUS参与者，而没有MGUS的参与者为12043人。在DXA测量的多变量logistic回归分析中，体脂百分比每增加1%，MGUS的几率增加4 % (aOR: 1.04, 95 % CI[1.01, 1.07])，非igm MGUS的几率增加6 % （aOR: 1.06, 95 % CI[1.02, 1.10]）。MGUS与其他肥胖指标（包括基线BMI、最大终生BMI、腰围、腰臀比和无脂质量）之间没有统计学上的显著关联。结论：我们的研究结果表明，肥胖与MGUS的发生率增加有关。然而，许多肥胖指标，包括常用的BMI，并没有充分捕捉到这种关联。

{"title":"The association between body fatness and prevalent MGUS in the U.S. general population","authors":"Mengmeng Ji , John H. Huber , Mei Wang , Tuo Lan , Graham A. Colditz , Shi-Yi Wang , Su-Hsin Chang","doi":"10.1016/j.canep.2026.103021","DOIUrl":"10.1016/j.canep.2026.103021","url":null,"abstract":"<div><h3>Objective</h3><div>Current evidence regarding the association between obesity and monoclonal gammopathy of undetermined significance (MGUS) remains inconsistent. This study aims to evaluate the relationship between objectively measured obesity markers and prevalent MGUS using nationally representative data from the U.S. population.</div></div><div><h3>Method</h3><div>Data came from the third National Health and Nutrition Examination Survey III (1988–1994) and continuous NHANES (1999–2004). We estimated multivariable-adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) for the association between MGUS and seven obesity markers (i.e., baseline body mass index (BMI), maximum lifetime BMI, waist circumference (WC), waist-hip ratio (WHR), total body fat, fat-free mass, and body fat percentage) using logistic regression. Body composition was assessed using dual-energy X-ray absorptiometry (DXA) in NHANES 1999–2004 and tetrapolar bioelectrical impedance analysis (BIA) in NHANES III.</div></div><div><h3>Results</h3><div>The study included 200 participants with MGUS in NHANES III (1988–1994) and 164 with MGUS in NHANES 1999–2004, compared with 12,043 participants without MGUS. In multivariate logistic regression analysis with DXA measurements, each 1 %age point increase in body fat percentage was associated with a 4 % higher odds of MGUS (aOR: 1.04, 95 % CI [1.01, 1.07]) and a 6 % higher odds of non-IgM MGUS (aOR: 1.06, 95 % CI [1.02, 1.10]). No statistically significant associations were found between MGUS and other obesity markers, including baseline BMI, maximum lifetime BMI, WC, WHR, and fat-free mass.</div></div><div><h3>Conclusion</h3><div>Our findings indicate that obesity is associated with an increased odds of MGUS. However, many obesity markers, including the commonly used BMI, do not adequately capture this association.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 103021"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146215069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence trends and survival of cervical cancer: A population-based study on Thai Cancer registry database 宫颈癌的发病率趋势和生存率：一项基于泰国癌症登记数据库的人群研究

IF 2.3 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2026-04-01 Epub Date: 2026-01-22 DOI: 10.1016/j.canep.2026.102992

Apirak Nguanboonmak , Boonyita Pakkaranang , Marut Yanaranop , Pichaya Tantiyavarong

Background

Cervical cancer remains common among Thai women, but nationwide evidence on incidence and survival is limited. This study analyzed trends over the past decade.

Methods

We conducted a nationwide, retrospective cohort study using data from the Thai national population-based cancer registry. The study included women diagnosed with cervical cancer between 2012 and 2022. Age-standardized incidence rates (ASR) were calculated using the WHO standard population. Relative survival was estimated using the Ederer II method, based on national life tables.

Results

A total of 47,220 newly diagnosed cervical cancer cases were included. The ASR ranged from 7.69 to 11.18 per 100,000 women. Incidence increased from 2012 to 2015 (slope = +0.43), then declined until 2021 (slope = –0.36), with a slight resurgence in 2022. Younger women (aged 30–39 years) exhibited a steadily increasing incidence trend. The overall 5-year relative survival rate was 75 % (95 % CI, 74–75 %), and survival rates at 1, 3, and 5 years declined progressively throughout the study period.

Conclusion

While cervical cancer incidence in Thailand declined overall from 2012 to 2022, rates increased among younger women. Relative survival also declined over time. These findings underscore the need to re-evaluate national screening strategies, particularly for younger populations, and to strengthen timely access to diagnosis and treatment.

宫颈癌在泰国妇女中仍然很常见，但全国范围内关于发病率和生存率的证据有限。这项研究分析了过去十年的趋势。方法：我们进行了一项全国性的回顾性队列研究，使用了泰国国家人口癌症登记处的数据。该研究包括2012年至2022年间被诊断患有宫颈癌的女性。使用世卫组织标准人群计算年龄标准化发病率（ASR）。根据国家生命表，使用Ederer II方法估计相对存活率。结果共纳入47220例新诊断宫颈癌病例。ASR从每10万名女性7.69到11.18不等。发病率从2012年到2015年上升（斜率= +0.43），然后下降到2021年（斜率= -0.36），2022年略有回升。年轻女性（30-39岁）发病率呈稳步上升趋势。总体5年相对生存率为75 %(95 % CI, 74-75 %)，在整个研究期间，1年、3年和5年的生存率逐渐下降。结论：虽然泰国的宫颈癌发病率从2012年到2022年总体下降，但年轻女性的发病率上升。相对存活率也随着时间的推移而下降。这些发现强调需要重新评估国家筛查战略，特别是针对年轻人群，并加强及时获得诊断和治疗。

{"title":"Incidence trends and survival of cervical cancer: A population-based study on Thai Cancer registry database","authors":"Apirak Nguanboonmak , Boonyita Pakkaranang , Marut Yanaranop , Pichaya Tantiyavarong","doi":"10.1016/j.canep.2026.102992","DOIUrl":"10.1016/j.canep.2026.102992","url":null,"abstract":"<div><h3>Background</h3><div>Cervical cancer remains common among Thai women, but nationwide evidence on incidence and survival is limited. This study analyzed trends over the past decade.</div></div><div><h3>Methods</h3><div>We conducted a nationwide, retrospective cohort study using data from the Thai national population-based cancer registry. The study included women diagnosed with cervical cancer between 2012 and 2022. Age-standardized incidence rates (ASR) were calculated using the WHO standard population. Relative survival was estimated using the Ederer II method, based on national life tables.</div></div><div><h3>Results</h3><div>A total of 47,220 newly diagnosed cervical cancer cases were included. The ASR ranged from 7.69 to 11.18 per 100,000 women. Incidence increased from 2012 to 2015 (slope = +0.43), then declined until 2021 (slope = –0.36), with a slight resurgence in 2022. Younger women (aged 30–39 years) exhibited a steadily increasing incidence trend. The overall 5-year relative survival rate was 75 % (95 % CI, 74–75 %), and survival rates at 1, 3, and 5 years declined progressively throughout the study period.</div></div><div><h3>Conclusion</h3><div>While cervical cancer incidence in Thailand declined overall from 2012 to 2022, rates increased among younger women. Relative survival also declined over time. These findings underscore the need to re-evaluate national screening strategies, particularly for younger populations, and to strengthen timely access to diagnosis and treatment.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"101 ","pages":"Article 102992"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146024977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0